Karyopharm Therapeutics I... (KPTI)
7.24
-0.71 (-8.93%)
At close: Mar 03, 2025, 3:59 PM
7.61
5.11%
After-hours: Mar 03, 2025, 04:01 PM EST
No 1D chart data available
| Bid | 7 |
| Market Cap | 60.93M |
| Revenue (ttm) | 9.9M |
| Net Income (ttm) | -5.21M |
| EPS (ttm) | -13.95 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -0.89 |
| Analyst | Buy |
| Ask | 9.24 |
| Volume | 130,564 |
| Avg. Volume (20D) | 81,968 |
| Open | 7.82 |
| Previous Close | 7.95 |
| Day's Range | 7.14 - 7.95 |
| 52-Week Range | 7.14 - 25.50 |
| Beta | 0.06 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezo...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2013
Employees 279
Stock Exchange NASDAQ
Ticker Symbol KPTI
Website https://www.karyopharm.com
Analyst Forecast
According to 4 analyst ratings, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $54, which is an increase of 645.86% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Karyopharm Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+17.86%
Karyopharm Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
